<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2024-39-1-126-134</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-2193</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Особенности хронической сердечной недостаточности на фоне тромбоцитопении у лиц, инфицированных вирусом иммунодефицита человека</article-title><trans-title-group xml:lang="en"><trans-title>Features of chronic heart failure on the background of thrombocytopenia in persons infected with the human immunodeficiency virus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3336-229X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горячева</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Goryacheva</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Горячева Ольга Георгиевна, канд. мед. наук, доцент кафедры поликлинической терапии</p><p>614000, Пермь, ул. Петропавловская, 26</p><p> </p></bio><bio xml:lang="en"><p>Olga G. Goryacheva, Cand. Sci. (Med.), Associate Professor, Department of Propaedeutic of Polyclinic Therapy</p><p>26, Petropavlovskaya str., Perm, 614000</p></bio><email xlink:type="simple">o.goryacheva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пермский государственный медицинский университет имени академика Е.А. Вагнера Министерства здравоохранения Российской Федерации (ПГМУ им. ак. Е.А. Вагнера Минздрава России),</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University (PSMU) named after academician E.A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>05</day><month>04</month><year>2024</year></pub-date><volume>39</volume><issue>1</issue><fpage>126</fpage><lpage>134</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Горячева О.Г., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Горячева О.Г.</copyright-holder><copyright-holder xml:lang="en">Goryacheva O.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/2193">https://www.sibjcem.ru/jour/article/view/2193</self-uri><abstract><p>Общий контекст исследования посвящен изучению особенностей течения хронической сердечной недостаточности (ХСН) у лиц, инфицированных вирусом иммунодефицита человека (ВИЧ), в рамках одномоментного скринингового клинического исследования.</p><sec><title>Цель</title><p>Цель: определить особенности течения ХСН у ВИЧ-инфицированных больных в зависимости от наличия тромбоцитопении (ТП).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В условиях многопрофильного стационара в течение 4 лет обследованы 240 больных с ВИЧ-инфекцией, среди которых выделена когорта больных с ХСН (160 человек), в дальнейшем разделенная на группы больных с ТП (107 человек) и без ТП (53 человека). Больным проведен одинаковый объем исследований, включающий эхокардиографию, неинвазивную артериографию, развернутое лабораторное обследование.</p></sec><sec><title>Результаты</title><p>Результаты. ТП у больных с ХСН и ВИЧ-инфекцией чаще встречается у курящих и лиц с вероятной алкогольной зависимостью и сопряжена с гемодинамическими нарушениями в виде более высоких цифр систолического (САД) и диастолического артериального давления (ДАД), увеличением левого предсердия. При ТП выше значения NT-proBNP плазмы крови, а в сыворотке крови – тканевого ингибитора металлопротеиназ-1 (TIMP-1), мочевины, билирубина, при этом концентрация ионов натрия и калия сыворотки крови ниже. Анемия и лейкопения чаще встречались в группе больных с ТП. Больные с ТП более привержены приему ингибиторов протеазы (ИП) и нестероидных противовоспалительных препаратов (НПВП).</p></sec><sec><title>Заключение</title><p>Заключение. Частота выявления ХСН у больных с ВИЧ-инфекцией на фоне ТП почти в 2 раза выше и чаще сопровождается дилатацией левого предсердия, более высокими цифрами АД, ростом TIMP-1 и снижением концентрации ионов калия в сыворотке крови. Концентрация NT-proBNP плазмы крови имеет тесную обратную корреляционную связь с количеством тромбоцитов у больных с ХСН и ТП, а наличие тяжелой ТП ≤ 30 × 109 клеток/л в 10,8 раза увеличивает шансы развития ХСН с низкой фракцией выброса (ФВ) левого желудочка (ЛЖ). Курение, возможная алкогольная зависимость и приверженность к приему ИП и НПВП являются значимыми факторами, связанными с развитием ТП у ВИЧ-инфицированных с ХСН.</p></sec></abstract><trans-abstract xml:lang="en"><p>The general context of the study is to review the characteristics of the course of chronic heart failure (CHF) in persons infected with the human immunodeficiency virus (HIV) as a part of a single-stage screening clinical trial.</p><sec><title>Aim</title><p>Aim: To determine the features of the CHF course in HIV-infected patients, depending on the presence of thrombocytopenia (TP).</p></sec><sec><title>Material and Methods</title><p>Material and Methods. In a multidisciplinary hospital, 240 patients with HIV infection were examined for four years, where a cohort of patients with CHF (160 people) was identified, further divided into groups of patients with TP (107 people) and without TP (53 people). Patients underwent the same amount of research, including echocardiography, non-invasive arteriography, and a detailed laboratory examination.</p></sec><sec><title>Results</title><p>Results. TP in patients with CHF and HIV infection is more common in smokers and people with alcohol dependence and is associated with hemodynamic disorders in the form of higher systolic and diastolic blood pressure, left atrium increase. With TP, the values of NT-proBNP in blood plasma are higher, and in the blood serum – tissue inhibitor of metalloproteinases-1, urea, bilirubin, while the concentration of sodium and potassium ions in the blood serum is lower. Anemia and leukopenia were more common in the group of patients with thrombocytopenia. Patients with TP are more adherent to taking protease inhibitors and non-steroidal anti-inflammatory drugs.</p></sec><sec><title>Conclusion</title><p>Conclusion. The frequency of CHF detection in patients with HIV infection against the background of TP is almost 2 times higher and is more often accompanied by dilatation of the left atrium, higher blood pressure, an increase in TIMP-1 and a decrease in the concentration of potassium ions in the blood serum. The concentration of NT-proBNP in blood plasma has a close inverse correlation with the number of platelets in patients with CHF and TP, and the presence of severe TP ≤ 30 × 109 cells/l increases the chances of developing CHF with low left ventricular ejection fraction by 10.8 times. Smoking, possible alcohol dependence and adherence to taking protease inhibitors and NSAIDs are significant factors associated with the development of thrombocytopenia in HIV-infected patients with CHF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>тромбоцитопения</kwd><kwd>ВИЧ-инфекция</kwd><kwd>артериальное давление</kwd><kwd>NT-proBNP</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>thrombocytopenia</kwd><kwd>HIV infection</kwd><kwd>blood pressure</kwd><kwd>NT-proBNP</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Greenberg E.M., Kaled E.S. Thrombocytopenia. Crit. Care Nurs. Clin. North Am. 2013;25(4):427–434. DOI: 10.1016/j.ccell.2013.08.003.</mixed-citation><mixed-citation xml:lang="en">Greenberg E.M., Kaled E.S. Thrombocytopenia. Crit. Care Nurs. Clin. North Am. 2013;25(4):427–434. DOI: 10.1016/j.ccell.2013.08.003.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Talargia F., Getacher L. Thrombocytopenia and associated factors among HIV infected patients in pre- and post-anti-retroviral therapy, North East Ethiopia. J. Blood Med. 2021;12:741–748. DOI: 10.2147/JBM.S323086.</mixed-citation><mixed-citation xml:lang="en">Talargia F., Getacher L. Thrombocytopenia and associated factors among HIV infected patients in pre- and post-anti-retroviral therapy, North East Ethiopia. J. Blood Med. 2021;12:741–748. DOI: 10.2147/JBM.S323086.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Belkin M.N., Uriel N. Heart health in the age of highly active antiretroviral therapy: a review of HIV cardiomyopathy. Curr. Opin. Cardiol. 2018;33(3):317–324. DOI: 10.1097/HCO.0000000000000513.</mixed-citation><mixed-citation xml:lang="en">Belkin M.N., Uriel N. Heart health in the age of highly active antiretroviral therapy: a review of HIV cardiomyopathy. Curr. Opin. Cardiol. 2018;33(3):317–324. DOI: 10.1097/HCO.0000000000000513.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Freiberg M.S., Chang C.H., Skanderson M., Patterson O.V., DuVall S.L., Brandt C.A. et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: Results from the veterans aging cohort study. JAMA Cardiol. 2017;2(5):536–546. DOI: 10.1001/jamacardio.2017.0264.</mixed-citation><mixed-citation xml:lang="en">Freiberg M.S., Chang C.H., Skanderson M., Patterson O.V., DuVall S.L., Brandt C.A. et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: Results from the veterans aging cohort study. JAMA Cardiol. 2017;2(5):536–546. DOI: 10.1001/jamacardio.2017.0264.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Barberato S.H., Romano M.M.D., Beck A.L.S., Rodrigues A.C.T., Almeida A.L.C., Assunção B.M.B.L. et al. Position statement on indications of echocardiography in adults – 2019. Arq. Bras. Cardiol. 2019;113(1):135– 181. DOI: 10.5935/abc.20190129.</mixed-citation><mixed-citation xml:lang="en">Barberato S.H., Romano M.M.D., Beck A.L.S., Rodrigues A.C.T., Almeida A.L.C., Assunção B.M.B.L. et al. Position statement on indications of echocardiography in adults – 2019. Arq. Bras. Cardiol. 2019;113(1):135– 181. DOI: 10.5935/abc.20190129.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Durandt C., Potgieter J.C., Mellet J., Herd C., Khoosal R., Nel J.G. et al. HIV and haematopoiesis. S. Afr. Med. J. 2019;109(8b):40–45. DOI: 10.7196/SAMJ.2019.v109i8b.13829.</mixed-citation><mixed-citation xml:lang="en">Durandt C., Potgieter J.C., Mellet J., Herd C., Khoosal R., Nel J.G. et al. HIV and haematopoiesis. S. Afr. Med. J. 2019;109(8b):40–45. DOI: 10.7196/SAMJ.2019.v109i8b.13829.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karki S., Deenadayalan V., Atluri R., Soon-Shiong R. Impact of thrombocytopenia on the outcomes of patients admitted with heart failure: Analysis of the National Inpatient Sample. Circulation. 2023;147:AP585. DOI: 10.1161/circ.147.suppl_1.P585.</mixed-citation><mixed-citation xml:lang="en">Karki S., Deenadayalan V., Atluri R., Soon-Shiong R. Impact of thrombocytopenia on the outcomes of patients admitted with heart failure: Analysis of the National Inpatient Sample. Circulation. 2023;147:AP585. DOI: 10.1161/circ.147.suppl_1.P585.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nascimento F.G., Tanaka P.Y. Thrombocytopenia in HIV-infected patients. Indian. J. Hematol. Blood Transfus. 2012;28(2):109–111. DOI: 10.1007/s12288-011-0124-9.</mixed-citation><mixed-citation xml:lang="en">Nascimento F.G., Tanaka P.Y. Thrombocytopenia in HIV-infected patients. Indian. J. Hematol. Blood Transfus. 2012;28(2):109–111. DOI: 10.1007/s12288-011-0124-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kyeyune R., Saathoff E., Ezaamama A.E., Löscher T., Fawzi W., Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect. Dis. 2014;14(1):496. DOI: 10.1186/1471-2334-14-496.</mixed-citation><mixed-citation xml:lang="en">Kyeyune R., Saathoff E., Ezaamama A.E., Löscher T., Fawzi W., Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect. Dis. 2014;14(1):496. DOI: 10.1186/1471-2334-14-496.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Alkholifi F.K., Abdi S.A.H., Qadri M. Global prevalence and associated clinical markers of thrombocytopenia in people living with HIV: Evidence from meta-analysis. Clin. Pract. 2022;12(6):867–875. DOI: 10.3390/clinpract12060091.</mixed-citation><mixed-citation xml:lang="en">Alkholifi F.K., Abdi S.A.H., Qadri M. Global prevalence and associated clinical markers of thrombocytopenia in people living with HIV: Evidence from meta-analysis. Clin. Pract. 2022;12(6):867–875. DOI: 10.3390/clinpract12060091.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Poulton J., Taylor C.M., De Giovanni J.V. Dilated cardiomyopathy associated with haemolytic uraemic syndrome. Br. Heart J. 1987;57(2):181– 183. DOI: 10.1136/hrt.57.2.181.</mixed-citation><mixed-citation xml:lang="en">Poulton J., Taylor C.M., De Giovanni J.V. Dilated cardiomyopathy associated with haemolytic uraemic syndrome. Br. Heart J. 1987;57(2):181– 183. DOI: 10.1136/hrt.57.2.181.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hitchcock I.S., Hafer M., Sangkhae V., Tucker J.A. The thrombopoietin receptor: revisiting the master regulator of platelet production. Platelets. 2021;32(6):770–778. DOI: 10.1080/09537104.2021.1925102.</mixed-citation><mixed-citation xml:lang="en">Hitchcock I.S., Hafer M., Sangkhae V., Tucker J.A. The thrombopoietin receptor: revisiting the master regulator of platelet production. Platelets. 2021;32(6):770–778. DOI: 10.1080/09537104.2021.1925102.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao B., Ye J.Y., Xu Y., Yang M. [Molecular mechanism of thrombopoietin signal pathways and its new effects]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(1):254–257. (In Chinese). DOI: 10.7534/j.issn.1009-2137.2013.01.052.</mixed-citation><mixed-citation xml:lang="en">Xiao B., Ye J.Y., Xu Y., Yang M. [Molecular mechanism of thrombopoietin signal pathways and its new effects]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(1):254–257. (In Chinese). DOI: 10.7534/j.issn.1009-2137.2013.01.052.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lupia E., Goffi A., Bosco O., Montrucchio G. Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases. Mediators Inflamm. 2012;2012:390892. DOI: 10.1155/2012/390892.</mixed-citation><mixed-citation xml:lang="en">Lupia E., Goffi A., Bosco O., Montrucchio G. Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases. Mediators Inflamm. 2012;2012:390892. DOI: 10.1155/2012/390892.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Simon F., Bergeron D., Larochelle S., Lopez-Vallé C.A., Genest H., Armour A. et al. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns. 2012;38(3):421–427. DOI: 10.1016/j.burns.2011.09.001.</mixed-citation><mixed-citation xml:lang="en">Simon F., Bergeron D., Larochelle S., Lopez-Vallé C.A., Genest H., Armour A. et al. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns. 2012;38(3):421–427. DOI: 10.1016/j.burns.2011.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fragao-Marcues M., Miranda I., Martins D., Barroso I., Mendes C., Pereira-Neves A. et al. Atrial matrix remodeling in atrial fibrillation patients with aortic stenosis. BMC Cardiovasc. Disord. 2020;20(1):468. DOI: 10.1186/s12872-020-01754-0.</mixed-citation><mixed-citation xml:lang="en">Fragao-Marcues M., Miranda I., Martins D., Barroso I., Mendes C., Pereira-Neves A. et al. Atrial matrix remodeling in atrial fibrillation patients with aortic stenosis. BMC Cardiovasc. Disord. 2020;20(1):468. DOI: 10.1186/s12872-020-01754-0.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">de Brouwer P., Bikker F.J., Brand H.S., Kaman W.E. Is TIMP-1 a biomarker for periodontal disease? A systematic review and meta-analysis. J. Periodontal. Res. 2022;57(2):235–245. DOI: 10.1111/jre.12957.</mixed-citation><mixed-citation xml:lang="en">de Brouwer P., Bikker F.J., Brand H.S., Kaman W.E. Is TIMP-1 a biomarker for periodontal disease? A systematic review and meta-analysis. J. Periodontal. Res. 2022;57(2):235–245. DOI: 10.1111/jre.12957.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jayashree K., Yasir M., Senthilkumar G.P., Ramesh Babu K., Mehalingam V., Mohanraj P.S. Circulating matrix modulators (MMP-9 and TIMP1) and their association with severity of diabetic retinopathy. Diabetes Metab. Syndr. 2018;12(6):869–873. DOI: 10.1016/j.dsx.2018.05.006.</mixed-citation><mixed-citation xml:lang="en">Jayashree K., Yasir M., Senthilkumar G.P., Ramesh Babu K., Mehalingam V., Mohanraj P.S. Circulating matrix modulators (MMP-9 and TIMP1) and their association with severity of diabetic retinopathy. Diabetes Metab. Syndr. 2018;12(6):869–873. DOI: 10.1016/j.dsx.2018.05.006.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mäkelä K., Kairisto V., Peltola O., Hollmén T., Virtanen A., Pulkki K. et al. Effect of platelet count on serum and plasma potassium: evaluation using database information from two hospitals. Scand. J. Clin. Lab. Invest. Suppl. 1995;222:95–100. DOI: 10.3109/00365519509088455.</mixed-citation><mixed-citation xml:lang="en">Mäkelä K., Kairisto V., Peltola O., Hollmén T., Virtanen A., Pulkki K. et al. Effect of platelet count on serum and plasma potassium: evaluation using database information from two hospitals. Scand. J. Clin. Lab. Invest. Suppl. 1995;222:95–100. DOI: 10.3109/00365519509088455.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Carpenito M., Fanti D., Mega S., Benfari G., Bono M.C., Rossi A. et al. The central role of left atrium in heart failure. Front. Cardiovasc. Med. 2021;8:704762. DOI: 10.3389/fcvm.2021.704762.</mixed-citation><mixed-citation xml:lang="en">Carpenito M., Fanti D., Mega S., Benfari G., Bono M.C., Rossi A. et al. The central role of left atrium in heart failure. Front. Cardiovasc. Med. 2021;8:704762. DOI: 10.3389/fcvm.2021.704762.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
